January round-up of pharma/biotech M&A activity

4 February 2017
mergers-acquisitions-big

The tone for pharmaceutical and biotechnology M&A activity in 2017 has very much been set in January, with six deals worth more than $500 million and three exceeding $1 billion.

Those include the deal that could well turn out to be the biggest of 2017, the $30 billion purchase of Swiss biotech Actelion by the US healthcare giant Johnson & Johnson (NYSE:JNJ).

US biotech Celgene (Nasdaq: CELG) and French pharma major Ipsen (Euronext: IPN) also showed an openness to add assets through costly acquisitions, and other big names including Swiss giant Roche (ROG: SIX) and the USA's Eli Lilly (NYSE: LLY) were active too.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical